12 tracked CMS actions, restated as marketing implications and planning questions. 6 are final, 2 are proposed and cannot support any external claim. The dates, titles and impact ratings are carried from the policy tracker so the two pages can never disagree; the marketing implication and the planning question are this site's analysis.
Who it affects: Public plan websites, comparison content, broker enablement
Marketing implication: Metrics move to public-facing sites rather than member portals, which makes them usable by anyone building a comparison, including competitors and reporters.
Planning question: Who owns the public page these metrics land on, and is marketing in the review path before it publishes?
Who it affects: Service-experience messaging, CAHPS-linked positioning
Marketing implication: Service claims are checkable against enforcement history. Anything promising speed of decision should be traceable to a measured number.
Planning question: Can every service-experience claim in the campaign be traced to an internal metric someone will stand behind?
Who it affects: Public-facing plan information, service-level comparisons, broker talking points
Marketing implication: Prior-authorization requirements and outcomes become publicly comparable. That turns an operational metric into a competitive one, in both directions.
Planning question: Have we seen where our published prior-authorization numbers land against the competitors in our priority counties?
Who it affects: PDP and MA-PD comparative messaging for AEP 2027
Marketing implication: Standalone drug plan premiums lose the subsidy that has been damping year-over-year increases, which changes the MA-PD versus PDP comparison a shopper makes.
Planning question: Does our AEP comparison story account for where PDP premiums land in our markets rather than where they landed last year?
Who it affects: Part D formulary strategy, C-SNP diabetes and cardiometabolic messaging, MA-PD member value stories
Marketing implication: GLP-1 coverage becomes a shoppable, high-salience difference at AEP. Any claim about GLP-1 access has to match the filed formulary exactly, product by product and plan year by plan year.
Planning question: Which of our products can substantiate a GLP-1 access claim for the plan year being marketed, and who signs off on the wording?
Who it affects: Benefit design, member-value messaging, competitive benefit comparisons
Marketing implication: The funding backdrop for 2027 benefit design is set. Benefit-richness messaging should be built against what the bid actually funds, not against last year's benefit set.
Planning question: Where our 2027 benefits move relative to 2026, does the campaign narrative still hold in the markets we are buying media in?
Who it affects: Part D cost messaging, dual and LIS communications
Marketing implication: A concrete, quotable beneficiary-facing number, and one that changes by plan year. Creative that carries a dollar figure needs a plan-year stamp.
Planning question: Does every piece of cost creative name the plan year it describes?
Who it affects: Part D messaging, pharmacy-counter cost narratives
Marketing implication: Proposed, so it cannot carry a benefit claim. It does change what a 2027 cost-of-drugs story can safely say once finalized.
Planning question: Do we have a hold on any creative that leans on negotiated-price savings until this is final?
Who it affects: Planning assumptions only
Marketing implication: Superseded by the April Rate Announcement. It is useful for reading direction of travel, and it is not a basis for any external claim.
Planning question: Is anything in the plan still built on Advance Notice numbers rather than the final announcement?
Who it affects: Star-based advertising claims, quality positioning, member communications
Marketing implication: A star rating used in advertising is tied to a specific contract and plan year. A methodology change that moves a rating moves what may be claimed the following cycle.
Planning question: Which star claims in our current creative are contract-specific and dated, and what is the plan if the October release moves them?
Who it affects: D-SNP positioning, integrated-product messaging, state-by-state strategy
Marketing implication: Integration status is a real, checkable product difference and it varies by state. A national D-SNP message will be wrong in most markets.
Planning question: In each priority state, is our D-SNP coordination-only, HIDE or FIDE, and does the local creative say the right thing?
Who it affects: Quality claims, vendor and TPMO oversight
Marketing implication: Enforcement is running on how quality performance is produced and described. Oversight of what downstream vendors and TPMOs say on a plan's behalf is part of marketing's exposure, not only compliance's.
Planning question: Do we have current attestations covering what our TPMOs and lead vendors are saying in our name?
The standing rule set governing MA and Part D communications and marketing, including what counts as marketing, disclaimer requirements, and the review path a material follows before use. Read the current version each cycle; it is amended by rulemaking and by sub-regulatory guidance.
Planning question: Is the team working from the current cycle's requirements, or from last year's deck?
Disclosure, recording and oversight obligations that attach to third parties marketing or generating leads on a plan's behalf. A plan carries the exposure for what its TPMOs say.
Planning question: Which TPMOs are in our funnel this cycle, and who checks their scripts and disclosures?
CMS issues model documents each contract year. Member-facing communications that restate benefits must line up with the filed versions for that plan year.
Planning question: Are our member communications reconciled against this year's filed model materials, not last year's?
Annual training and testing obligations that gate who may sell, which in turn gates when distribution capacity is actually available in a season.
Planning question: Does our launch date assume a field that has finished certification?
Rules governing consent for contact and what may be done with beneficiary data obtained through marketing. This site's own guardrail is stricter than the floor: it publishes aggregate geography-level intelligence only and never individual-level targeting.
Planning question: Can every lead source in the plan show valid consent, and is any audience segment built on health status?
| Status | What it means for a campaign |
|---|---|
| FINAL | A final rule, final announcement, or completed CMS action. |
| PROPOSED | Published for comment. Plan against it, do not build creative on it. |
| GUIDANCE | Sub-regulatory guidance, memo, or program announcement. |
| ENFORCEMENT | A CMS enforcement action. Precedent, not rulemaking. |
Status is the single most important field on this page. Building creative on a proposed rule is the most expensive avoidable mistake in Medicare marketing.
Most marketing rework in this category is caused by three things: a claim built on a proposed rule, a benefit or star claim carried over from the previous plan year, and a third party saying something in the plan’s name that the plan never approved. Every item on this page maps to one of those three failure modes.